Antineoplastic Combined Chemotherapy Protocols

"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.

Descriptor ID	D000971
MeSH Number(s)	E02.183.750.500 E02.319.077.500 E02.319.310.037
Concept/Terms	Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Combined Antineoplastic Agents Antineoplastic Agents, Combined Agent, Combined Antineoplastic Agents, Combined Antineoplastic Antineoplastic Agent, Combined Combined Antineoplastic Agent Antineoplastic Combined Chemotherapy Regimens Drug Combinations, Antineoplastic Anticancer Drug Combinations Anticancer Drug Combination Drug Combination, Anticancer Drug Combinations, Anticancer Antineoplastic Drug Combinations Antineoplastic Drug Combination Combinations, Antineoplastic Drug Drug Combination, Antineoplastic Antineoplastic Chemotherapy Protocols Antineoplastic Chemotherapy Protocols Antineoplastic Chemotherapy Protocol Chemotherapy Protocol, Antineoplastic Protocol, Antineoplastic Chemotherapy Protocols, Antineoplastic Chemotherapy Cancer Chemotherapy Protocols Cancer Chemotherapy Protocol Chemotherapy Protocol, Cancer Chemotherapy Protocols, Cancer Protocol, Cancer Chemotherapy Protocols, Cancer Chemotherapy Chemotherapy Protocols, Antineoplastic

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Clinical Protocols [E02.183]
Antineoplastic Protocols [E02.183.750]
Antineoplastic Combined Chemotherapy Protocols [E02.183.750.500]
Drug Therapy [E02.319]
Antineoplastic Protocols [E02.319.077]
Antineoplastic Combined Chemotherapy Protocols [E02.319.077.500]
Drug Therapy, Combination [E02.319.310]
Antineoplastic Combined Chemotherapy Protocols [E02.319.310.037]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Combined Chemotherapy Protocols".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.

Bar chart showing 241 publications over 27 distinct years, with a maximum of 18 publications in 2019 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	2	2
1995	3	0	3
1997	1	0	1
1998	3	1	4
1999	3	1	4
2000	1	1	2
2001	1	0	1
2002	3	0	3
2003	3	1	4
2004	5	1	6
2005	6	2	8
2006	10	1	11
2007	8	1	9
2008	15	0	15
2009	10	2	12
2010	8	1	9
2011	12	3	15
2012	9	3	12
2013	10	2	12
2014	11	0	11
2015	12	5	17
2016	8	3	11
2017	12	3	15
2018	9	5	14
2019	16	2	18
2020	13	5	18
2021	3	1	4

Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.

Bundred N, Porta N, Brunt AM, Cramer A, Hanby A, Shaaban AM, Rakha EA, Armstrong A, Cutress RI, Dodwell D, Emson MA, Evans A, Hartup SM, Horgan K, Miller SE, McIntosh SA, Morden JP, Naik J, Narayanan S, Ooi J, Skene AI, Cameron DA, Bliss JM. Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clin Cancer Res. 2022 Apr 01; 28(7):1323-1334.

View in: PubMed
Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 03 01; 28(5):882-892.

View in: PubMed
Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.

View in: PubMed
duPont NC, Enserro D, Brady MF, Moxley K, Walker JL, Cosgrove C, Bixel K, Tewari KS, Thaker P, Wahner Hendrickson AE, Rubin S, Fujiwara K, Casey AC, Soper J, Burger RA, Monk BJ. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2022 02; 164(2):398-405.

View in: PubMed
Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, Percent IJ, Molina AM, Cho DC, Bendell JC, Gordan LN, Rezazadeh Kalebasty A, George DJ, Hutson TE, Arrowsmith ER, Zhang J, Zoco J, Johansen JL, Leung DK, Tykodi SS. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 2022 03 01; 128(5):966-974.

View in: PubMed
Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.

View in: PubMed
Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2022 01 01; 28(1):36-44.

View in: PubMed
Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, Fidler MJ, Stenson K, Vasan NR, Razaq MA, Campana J, Ha P, Mann G, Ishida K, Garcia-Guzman M, Biel M, Gillenwater AM. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.

View in: PubMed
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.

View in: PubMed
Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.

View in: PubMed

People

Explore

Similar Concepts

Top Journals